内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

《2013年版中国2型糖尿病防治指南（征求意见稿）》出炉！

2013-11-25 cmt 医学论坛网

2013年版中国2型糖尿病防治指南
关注

11月22日上午，《2013年版中国2型糖尿病防治指南（征求意见稿）》在中华医学会糖尿病学分会第十七次全国学术会议(CDS2013)会上发布，《中国医学论坛报》、全媒体报道团队正在前方为您整理征求意见稿中指南的最新变化，前方记者说：在糖尿病特殊情况中，新增了糖尿病与口腔疾病部分；糖尿病合并感染的防治有了较大更改；重大改变是二线治疗后只有主要治疗路径，没有备选路径了…… 2型糖尿病

11月22日上午，《2013年版中国2型糖尿病防治指南（征求意见稿）》在中华医学会糖尿病学分会第十七次全国学术会议(CDS2013)会上发布，《中国医学论坛报》、全媒体报道团队正在前方为您整理征求意见稿中指南的最新变化，前方记者说：在糖尿病特殊情况中，新增了糖尿病与口腔疾病部分；糖尿病合并感染的防治有了较大更改；重大改变是二线治疗后只有主要治疗路径，没有备选路径了……

2型糖尿病高血糖治疗路径

图为指南建议的2型糖尿病高血糖治疗路径。深色路径是根据药物卫生经济学、疗效和安全性等方面的临床证据以及我国国情等因素权衡考虑后推分糖尿病指南中建议的药物治疗路径相似。浅色路径为与深色路径相应的备选路径。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009735, encodeId=b1562009e357f, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jul 27 11:42:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078298, encodeId=fba020e829819, content=<a href='/topic/show?id=b6c09e42962' target=_blank style='color:#2F92EE;'>#防治指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97429, encryptionId=b6c09e42962, topicName=防治指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Feb 14 22:42:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949885, encodeId=17a71949885ef, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 25 03:42:00 CST 2014, time=2014-01-25, status=1, ipAttribution=)]
    2014-07-27 smlt2008

    #征求意见稿#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2009735, encodeId=b1562009e357f, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jul 27 11:42:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078298, encodeId=fba020e829819, content=<a href='/topic/show?id=b6c09e42962' target=_blank style='color:#2F92EE;'>#防治指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97429, encryptionId=b6c09e42962, topicName=防治指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Feb 14 22:42:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949885, encodeId=17a71949885ef, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 25 03:42:00 CST 2014, time=2014-01-25, status=1, ipAttribution=)]
    2014-02-14 bioon3

    #防治指南#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2009735, encodeId=b1562009e357f, content=<a href='/topic/show?id=8d6750352ef' target=_blank style='color:#2F92EE;'>#征求意见稿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50352, encryptionId=8d6750352ef, topicName=征求意见稿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jul 27 11:42:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078298, encodeId=fba020e829819, content=<a href='/topic/show?id=b6c09e42962' target=_blank style='color:#2F92EE;'>#防治指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97429, encryptionId=b6c09e42962, topicName=防治指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Feb 14 22:42:00 CST 2014, time=2014-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949885, encodeId=17a71949885ef, content=<a href='/topic/show?id=f8c0503517b' target=_blank style='color:#2F92EE;'>#征求意见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50351, encryptionId=f8c0503517b, topicName=征求意见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jan 25 03:42:00 CST 2014, time=2014-01-25, status=1, ipAttribution=)]
    2014-01-25 zhaohui6731

    #征求意见#

    0